These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

775 related items for PubMed ID: 17671378

  • 1. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.
    Bastemir M, Akin F, Yaylali GF.
    Neuroendocrinology; 2007; 86(2):119-23. PubMed ID: 17671378
    [Abstract] [Full Text] [Related]

  • 2. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M, Matovinovic M, Vrkljan M.
    Croat Med J; 2007 Feb; 48(1):87-91. PubMed ID: 17309144
    [Abstract] [Full Text] [Related]

  • 3. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM.
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [Abstract] [Full Text] [Related]

  • 4. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial.
    Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, Ferrara R, Mainini F, Arosio M, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):342-51. PubMed ID: 16487447
    [Abstract] [Full Text] [Related]

  • 5. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC, Lugao HB, Pereira MC, Machado HR, Castro Md, Moreira AC.
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA, Wu Z, Silva CM, Barbosa FR, Dias JS, Schrank Y, Strasburger CJ, Gadelha MR.
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [Abstract] [Full Text] [Related]

  • 7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 8. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E, Minuto F, Colao A, Ferone D.
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [Abstract] [Full Text] [Related]

  • 9. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [Abstract] [Full Text] [Related]

  • 10. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S, Gasco V, Ragazzoni F, Ghigo E.
    J Endocrinol Invest; 2003 Sep; 26(10 Suppl):27-35. PubMed ID: 15497657
    [Abstract] [Full Text] [Related]

  • 11. Value of growth hormone dynamics and somatomedin C (insulin-like growth factor I) levels in predicting the long-term benefit after transsphenoidal surgery for acromegaly.
    Arafah BM, Rosenzweig JL, Fenstermaker R, Salazar R, McBride CE, Selman W.
    J Lab Clin Med; 1987 Mar; 109(3):346-54. PubMed ID: 3102658
    [Abstract] [Full Text] [Related]

  • 12. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly.
    Colao A, Pivonello R, Cavallo LM, Gaccione M, Auriemma RS, Esposito F, Cappabianca P, Lombardi G.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):250-6. PubMed ID: 16886969
    [Abstract] [Full Text] [Related]

  • 13. Pregnancy-induced changes in insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 3 (IGFBP-3), and acid-labile subunit (ALS) in patients with growth hormone (GH) deficiency and excess.
    Wiesli P, Zwimpfer C, Zapf J, Schmid C.
    Acta Obstet Gynecol Scand; 2006 Aug; 85(8):900-5. PubMed ID: 16862465
    [Abstract] [Full Text] [Related]

  • 14. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
    Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC.
    Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
    [Abstract] [Full Text] [Related]

  • 15. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD.
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [Abstract] [Full Text] [Related]

  • 16. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.
    Kreutzer J, Jeske I, Hofmann B, Blumcke I, Fahlbusch R, Buchfelder M, Buslei R.
    Clin Neuropathol; 2009 Aug; 28(6):430-9. PubMed ID: 19919817
    [Abstract] [Full Text] [Related]

  • 17. GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment.
    Colao A, Terzolo M, Bondanelli M, Galderisi M, Vitale G, Reimondo G, Ambrosio MR, Pivonello R, Lombardi G, Angeli A, degli Uberti EC.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):613-20. PubMed ID: 18410555
    [Abstract] [Full Text] [Related]

  • 18. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE, Thornton-Jones VA, Wass JA.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [Abstract] [Full Text] [Related]

  • 19. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 20. Homocysteine levels in acromegaly patients.
    Hekimsoy Z, Ozmen B, Ulusoy S.
    Neuro Endocrinol Lett; 2005 Dec; 26(6):811-4. PubMed ID: 16380700
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.